Northwestern University Engineers Bioelectronic Implant Capable of Continuous Multi-Drug Delivery From Within the Body

Northwestern's HOBIT device uses bioelectronics to keep engineered cells alive, creating a long-term internal pharmacy for continuous drug delivery.

By: AXL Media

Published: Mar 28, 2026, 5:06 AM EDT

Source: Information for this report was sourced from Northwestern University

A Hybrid Solution for Chronic Disease Management

The emergence of the HOBIT system marks a significant shift in how chronic conditions, ranging from diabetes to metabolic disorders, might be managed without the need for patient intervention. By integrating living, engineered cells with sophisticated bioelectronics, the research team has created a self-sustaining environment that produces therapeutic proteins directly inside the patient. This hybrid approach seeks to eliminate the traditional burdens of medication adherence, such as frequent injections or strict oral dosing schedules, by replacing them with a programmable internal factory.

Overcoming the Oxygen Barrier in Cellular Implants

The primary technical hurdle for implantable "living pharmacies" has historically been the high rate of cell death caused by oxygen deprivation. When therapeutic cells are densely packed into a small protective chamber, they quickly exhaust the local oxygen supply, leading to a rapid decline in drug production. According to Jonathan Rivnay, the lead device developer at Northwestern, the HOBIT platform addresses this by splitting water molecules to generate oxygen on-site. This localized production allowed for cell densities roughly six times higher than those seen in traditional, non-oxygenated encapsulation methods.

Sustaining Complex Therapeutic Regimens Simultaneously

In a major breakthrough for multi-drug therapy, the researchers engineered cells to produce an anti-HIV antibody, a GLP-1-like peptide for diabetes, and the appetite-regulating hormone leptin. Traditionally, these biologics possess vastly different half-lives, making it difficult to maintain stable concentrations in the bloodstream through external dosing. The study demonstrated that the HOBIT device could stabilize all three therapies at once, providing a steady release that mirrors the body’s natural hormonal regulation rather than the "peaks and valleys" associated with manual injections.